J 2020

The association of lorg-term outcome and biological sex in patients with acute heart failure from different geographic regions

MOTIEJUNAITE, J., E. AKIYAMA, A. COHEN-SOLAL, A. P. MAGGIONI, C. MUELLER et. al.

Základní údaje

Originální název

The association of lorg-term outcome and biological sex in patients with acute heart failure from different geographic regions

Autoři

MOTIEJUNAITE, J. (440 Litva), E. AKIYAMA (392 Japonsko), A. COHEN-SOLAL (250 Francie), A. P. MAGGIONI (380 Itálie), C. MUELLER (756 Švýcarsko), D. J. CHOI (178 Konžská republika), A. KAVOLIUNIENE (440 Litva), J. CELUTKIENE (440 Litva), Jiří PAŘENICA (203 Česká republika, domácí), J. LASSUS (246 Finsko), K. KAJIMOTO (392 Japonsko), N. SATO (392 Japonsko), O. MIRO (724 Španělsko), W. F. PEACOCK (840 Spojené státy), Y. MATSUE (392 Japonsko), A. A. VOORS (528 Nizozemské království), C. S. P. LAM (702 Singapur), J. A. EZEKOWITZ (124 Kanada), A. AHMED (840 Spojené státy), G. C. FONAROW (840 Spojené státy), E. GAYAT (250 Francie), V. REGITZ-ZAGROSEK (276 Německo) a A. MEBAZAA (250 Francie, garant)

Vydání

European heart journal, Oxford, Oxford University Press, 2020, 0195-668X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 29.983

Kód RIV

RIV/00216224:14110/20:00116018

Organizační jednotka

Lékařská fakulta

UT WoS

000522664500012

Klíčová slova anglicky

Acute heart failure; Gender; Biological sex; Mortality; Prognosis

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 12. 5. 2021 13:15, Mgr. Tereza Miškechová

Anotace

V originále

Aims Recent data from national registries suggest that acute heart failure (AHF) outcomes might vary in men and women, however, it is not known whether this observation is universal. The aim of this study was to evaluate the association of biological sex and 1-year all-cause mortality in patients with AHF in various regions of the world. Methods and Results We analysed several AHF cohorts including GREAT registry (22 523 patients, mostly from Europe and Asia) and OPTIMIZE-HF (26 376 patients from the USA). Clinical characteristics and medication use at discharge were collected. Hazard ratios (HRs) for 1-year mortality according to biological sex were calculated using a Cox proportional hazards regression model with adjustment for baseline characteristics (e.g. age, comorbidities, clinical and laboratory parameters at admission, Left ventricular ejection fraction). In the GREAT registry, women had a Lower risk of death in the year following AHF [HR 0.86 (0.79-0.94), P< 0.001 after adjustment]. This was mostly driven by northeast Asia [n=9135, HR 0.76 (0.67-0.87), P< 0.001], while no significant differences were seen in other countries. In the OPTIMIZE-HF registry, women also had a tower risk of 1-year death [HR 0.93 (0.89-0.97), P < 0.001]. In the GREAT registry, women were less often prescribed with a combination of angiotensin-converting enzyme inhibitors and beta-Mockers at discharge (50% vs. 57%, P = 0.001). Conclusion Globally women with AHF have a lower 1-year mortality and less evidenced-based treatment than men. Differences among countries need further investigation. Our findings merit consideration when designing future global clinical trials in AHF.